FTC, Valeant See Eye-To-Eye On Paragon Divestiture

Law360, New York (February 8, 2017, 5:35 PM EST) -- The U.S. Federal Trade Commission signed off on a settlement with Valeant Pharmaceuticals International Inc. over its 2015 purchase of a contact lens manufacturer, finding on Wednesday that the Canadian pharmaceutical company's divestiture remedied the agency's claims.

Valeant — the owner of Bausch & Lomb, an eye health company and maker of contact lenses — sold off its Paragon Holdings I Inc. unit in November, at the behest of the federal antitrust watchdog. That sale adequately addressed the agency's competition concerns in the market for polymer disks used to make rigid, gas-permeable contact lenses, according to the Wednesday final order settling...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!